# MiNK Therapeutics, Inc. (INKT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INKT
## Company Profile
- Ticker: INKT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 11.36 USD
- Market cap: 59583512.04000001 USD
- Last updated: 2026-08-12
## Business Overview
### Allogeneic iNKT Cell Therapy Company
MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction.
### AgenT-797 Lead Asset
AgenT-797 is an off-the-shelf, cryopreserved iNKT-cell therapy that does not require lymphodepletion or HLA matching. These characteristics may support use in severe acute lung injury, critical illness, and other settings involving immune dysregulation.
### Off-the-Shelf Treatment Model
The ability to store and administer AgenT-797 without patient-specific manufacturing is central to its intended use. This model may be particularly relevant in acute-care settings where rapid treatment and simplified logistics are important.
### Multi-Indication Expansion
AgenT-797 is being studied in solid tumors, graft-versus-host disease, and critical pulmonary immune failure. MiNK also has TCR-based and neoantigen-targeted iNKT programs intended to achieve tissue-specific immune activation.
## Why The Stock Is Moving

The latest monitored company update is “MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Additional randomized Phase 2 data for agenT-797 in acute lung injury and ARDS in 2027.

## Recent News
- 2026-08-13 11:30 EST — [MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury](https://biopharmsignal.com/news/INKT/mink-therapeutics-reports-second-quarter-2026-financial-results-and-reports-obse-a3474627) — Source: MiNK Therapeutics, Inc.
- 2026-08-06 16:00 EST — [MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium](https://biopharmsignal.com/news/INKT/mink-therapeutics-presents-early-observations-from-ongoing-phase-2-trial-at-the--34378519) — Source: MiNK Therapeutics, Inc.
- 2026-08-06 12:19 EST — [MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates](https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-second-quarter-2026-financial-results-provide-clinic-55e96291) — Source: MiNK Therapeutics, Inc.
- 2026-06-03 20:30 EST — [MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting](https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-its-virtual-2026-annual-shareholders-meeting-57694aec) — Source: MiNK Therapeutics, Inc.
- 2026-05-28 13:04 EST — [MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness](https://biopharmsignal.com/news/INKT/mink-therapeutics-announces-first-patient-dosed-in-randomized-phase-2-trial-of-a-116222e3) — Source: MiNK Therapeutics, Inc.